OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance
Record Third Quarter 2026 Revenue of $72.7 Million , Up 19% Year-over-Year WARSAW, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- ...
Model output · Signal date 2026-11-06
Orthopediatrics Corp (KIDS) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
40.0%
Spearman, 357 dates
Market Cap
$829M
small-cap · #40 of 60 peers
Summary
Orthopediatrics Corp (KIDS) stock forecast summary
Our AI scores Orthopediatrics Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Orthopediatrics Corp is a small-cap company with a market capitalization of $829M. It ranks number 40 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For KIDS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 40.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, KIDS included.
Price
KIDS price chart and AI forecast
Cross-section · 2026-11-06
How KIDS ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Orthopediatrics Corp (KIDS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | KIDS | Rank |
|---|---|---|
| Market Cap | $829M | 40/60 |
| P/B Ratio | 2.44x | 41/55 |
| EPS | $-1.44 | – |
| Book Value/Share | $13.00 | – |
| Revenue/Share | $10.12 | – |
| FCF/Share | $0.12 | – |
Profitability & Margins
| Metric | KIDS | Rank |
|---|---|---|
| ROE | -10.0% | 22/40 |
| ROA | -6.7% | 25/43 |
| ROIC | -5.5% | 32/54 |
| Gross Margin | 73.8% | 18/54 |
| Operating Margin | -9.4% | 37/55 |
| Net Margin | -12.8% | 27/42 |
| EBT Margin | -12.7% | 39/55 |
| Tax Rate | -0.9% | – |
Financial Health
| Metric | KIDS | Rank |
|---|---|---|
| Current Ratio | 4.55x | 22/59 |
| Quick Ratio | 2.00x | 31/55 |
| D/E Ratio | 0.50x | 31/56 |
| Financial Leverage | 1.50x | 30/54 |
| Interest Coverage | -1.5x | 31/50 |
| Working Capital | $198M | 34/59 |
Cash Flow
| Metric | KIDS | Rank |
|---|---|---|
| Operating Cash Flow | $12M | 35/56 |
| Free Cash Flow | $3M | 27/50 |
| Capital Spending | -$9M | 19/50 |
| FCF/Sales | 1.2% | 26/50 |
| CapEx/Sales | 3.5% | 24/50 |
Operational Efficiency
| Metric | KIDS | Rank |
|---|---|---|
| Asset Turnover | 0.52x | 40/52 |
| Receivables Turnover | 4.4x | 47/52 |
| Inventory Turnover | 0.5x | 52/52 |
| Fixed Assets Turnover | 5.6x | 35/54 |
| Days Sales Outstanding | 82 days | 6/52 |
| Days Inventory | 747 days | 1/52 |
| Payables Period | 129 days | 6/47 |
| Cash Conversion Cycle | 701 days | 1/42 |
Income Statement
| Metric | KIDS | Rank |
|---|---|---|
| Total Revenue | $264M | 38/54 |
| Operating Income | -$25M | 33/56 |
| Net Income | -$34M | 25/43 |
| R&D Expense | $9M | 51/53 |
| SG&A Expense | $232M | 34/54 |
| Cost of Goods Sold | $69M | 36/54 |
Dividend & Shareholder Information
| Metric | KIDS | Rank |
|---|---|---|
| Shares Outstanding | 26M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $253M | 49.7% of assets |
| Cash & Short-term Investments | $17M | 3.4% of assets |
| Accounts Receivable | $60M | 11.7% of assets |
| Inventory | $142M | 27.9% of assets |
| Total Liabilities | $170M | 33.3% of assets |
| Short-term Debt | $31M | 6.1% of assets |
Quarterly Financial Reports
KIDS quarterly financials and insider trading
Industry Peers · Surgical & Medical Instruments & Apparatus
Orthopediatrics Corp (KIDS) industry peers
Companies classified under the same SEC industry code as Orthopediatrics Corp (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| KIDS Orthopediatrics Corp | $829M | |
| SYK Stryker Corp | $127.56B | |
| MMM 3m Co | $95.67B | |
| BSX Boston Scientific Corp | $61.95B | |
| BDX Becton Dickinson & Co | $57.71B | |
| MDLN Medline Inc. | $52.27B | |
| RMD Resmed Inc | $33.10B | |
| DXCM Dexcom Inc | $29.62B | |
| WST West Pharmaceutical Services Inc | $27.85B | |
| SOLV Solventum Corp | $14.84B | |
| BAX Baxter International Inc | $13.34B | |
| GKOS Glaukos Corp | $13.28B | |
| PEN Penumbra Inc | $12.66B | |
| GMED Globus Medical Inc | $10.93B | |
| PODD Insulet Corp | $10.16B | |
| TFX Teleflex Inc | $6.39B | |
| HAE Haemonetics Corp | $5.46B | |
| MMSI Merit Medical Systems Inc | $5.23B | |
| MMED Minimed Group, Inc. | $4.70B | |
| HTFL Heartflow, Inc. | $4.52B | |
| ICUI Icu Medical Inc/De | $4.30B | |
| PLSE Pulse Biosciences, Inc. | $3.80B | |
| STVN Stevanato Group S.P.A. | $3.71B | |
| ATRC Atricure, Inc. | $2.98B | |
| IRTC Irhythm Holdings, Inc. | $2.97B | |
| UFPT Ufp Technologies Inc | $2.35B | |
| LMAT Lemaitre Vascular Inc | $1.85B | |
| INSP Inspire Medical Systems, Inc. | $1.85B | |
| KMTS Kestra Medical Technologies, Ltd. | $1.72B | |
| NVCR Novocure Ltd | $1.55B | |
| TNDM Tandem Diabetes Care Inc | $1.25B | |
| SGP Spyglass Pharma, Inc. | $1.24B | |
| PRCT Procept Biorobotics Corp | $1.18B | |
| DRTS Alpha Tau Medical Ltd. | $1.17B | |
| ATEC Alphatec Holdings, Inc. | $1.15B | |
| IRMD Iradimed Corp | $1.10B | |
| SIBN Si-Bone, Inc. | $1.09B | |
| IART Integra Lifesciences Holdings Corp | $1.04B | |
| AORT Artivion, Inc. | $985M | |
| BBNX Beta Bionics, Inc. | $854M | |
| BVS Bioventus Inc. | $727M | |
| TCMD Tactile Systems Technology Inc | $590M | |
| SGHT Sight Sciences, Inc. | $555M | |
| DCTH Delcath Systems, Inc. | $527M | |
| ANGO Angiodynamics Inc | $493M | |
| RCEL Avita Medical, Inc. | $485M | |
| MDXG Mimedx Group, Inc. | $478M | |
| BWAY Brainsway Ltd. | $437M | |
| NPCE Neuropace Inc | $436M | |
| SSII Ss Innovations International, Inc. | $429M | |
| CERS Cerus Corp | $407M | |
| CARL Carlsmed, Inc. | $396M | |
| MOBI Mobia Medical, Inc. | $373M | |
| EMBC Embecta Corp. | $351M | |
| OBIO Orchestra Biomed Holdings, Inc. | $341M | |
| OFIX Orthofix Medical Inc. | $321M | |
| CLPT Clearpoint Neuro, Inc. | $276M | |
| PROF Profound Medical Corp. | $263M | |
| TMCI Treace Medical Concepts, Inc. | $262M | |
| OSUR Orasure Technologies Inc | $232M |
Where KIDS sits on the market map
Industrial Applications and Services · Surgical & Medical Instruments & Apparatus
News
Orthopediatrics Corp (KIDS) stock news
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
OrthoPediatrics Corp. projects FY2026 revenue of $270.0 to $273.0 million
OrthoPediatrics Corp. has updated its financial guidance for the full year 2026 in an investor presentation dated October ...
FAQ
Orthopediatrics Corp (KIDS) stock forecast FAQ
What is the Orthopediatrics Corp (KIDS) stock forecast?
Our AI scores Orthopediatrics Corp every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Orthopediatrics Corp stock predictions?
For KIDS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 40.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Orthopediatrics Corp forecasts updated?
Orthopediatrics Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Orthopediatrics Corp's industry peers?
60 issuers in our coverage, KIDS included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.